Millennium Research Group has conducted a detailed analysis of the orthopedic biomaterials market in its US Markets for Orthopedic Biomaterials 2007 report and forecasts that stem cell products will be the fastest-growing segment over the next 5 years, growing at a compound annual growth rate of almost 50% to reach a value of almost $200 million by 2011.

"Driving this growth are new, premium-priced products such as Osiris Therapeutics' Osteocel, Stryker Biotech's OP-1 and Medtronic Spinal and Biologics' INFUSE, the latter of which surgeons call magic dust due to its effectiveness," said Kevin Flewwelling, senior analyst at MRG. "These products are not only popular with physicians but also help patients by eliminating the need for a second painful autograft".

US Markets for Orthopedic Biomaterials is part of a global series that also includes separate reports on Europe and Japan. Companies covered in this report series include Medtronic Spinal and Biologics, Synthes, DePuy, Osteotech, Smith & Nephew, Biomet, IsoTis OrthoBiologics, Orthovita, Osiris Therapeutics, Genzyme, Sanofi-Synthelabo, Seikagaku, Fidia, Chugai Pharmaceutical, Pentax Corporation, Olympus Biomaterial, Bioniche, Q-Med and Chemedica.

About Stem Cells and Bone Growth Factor Products

Mesenchymal Stem Cells (MSCs) can differentiate into a variety of adult tissue cells. When tissue is damaged, MCSs are released and travel to the site of tissue injury. By implanting stem cells at a fracture site, surgeons can dramatically reduce rehabilitation time, and improve patient outcomes. Growth factors consist of proteins which signal the body to produce bone at a much faster rate than it otherwise would.

About Millennium Research Group

Millennium Research Group (, a Decision Resources, Inc. company (, is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:
FCMN Contact:

SOURCE: Millennium Research Group

CONTACT: Amy Krohn of Millennium Research Group, +1-416-364-7776 x101,

Antibacterial Agents, Including Drugs from Pfizer and Johnson & Johnson/Basilea, Will Take Share from Widely Used Vancomycin

View Now